145 results about "Anticancer treatment" patented technology

The invention discloses an intelligent anti-cancer science popularization content recommendation method and system based on patient big data, and the method comprises the following steps: collecting patient data, including static data and behavior data, the behavior data including search history, click record, browsing duration, activity participation record, and reading content; extracting user features from the patient data, and generating a user portrait; anti-cancer popular science contents in the platform are collected, and labels are added to the popular science anti-cancer contents by using a natural language processing technology and a machine learning algorithm; constructing a content recommendation engine for dynamically matching the user portrait with the tag; according to the matching result of the content recommendation engine, generating a personalized content recommendation list in combination with the current anti-cancer treatment stage of the patient; and transmitting the recommended content by using multiple channels according to the content recommendation list. According to the method, the user portrait is constructed through the multi-dimensional data of the patient, so that the pertinence and adaptability of recommendation can be effectively improved.

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring therapy can be used for prognostic (predictive) purposes to thereby treat an individual having cancer. Accordingly, one aspect of the present invention relates to methods of treating a subject having cancer by determining the amount and / or activity level of ZNFX1 in the context of a biological sample (e.g., blood, serum, cells, or tissue) to thereby determine whether an individual afflicted with a cancer is likely to respond to anti-cancer therapy, whether in an original or recurrent cancer.

Provided herein are combination therapies, and methods of treating diseases and / or conditions with combination therapies; wherein the combination can include PolQ inhibitor and a second anti-cancer therapeutic agent; and the PolQ inhibitor is represented by the compounds of Formula (I).

The present invention relates to the field of anticancer treatments. In particular, the present invention concerns therapeutic compositions for use in combination with immune modulatory treatments (IMTs) for treating cancers. The present invention also concerns kits of parts comprising said compositions and immune modulatory treatments. The present invention further concerns in vitro methods for screening said compositions.

The present invention relates to a polypeptide-drug conjugate that binds to IL4Ra and a use thereof, and provides: a polypeptide comprising a ligand that specifically binds to IL4Ra and a temperature-responsive disordered domain; and a polypeptide-drug conjugate in which a cytotoxic drug is bound to the polypeptide. More specifically, the polypeptide, in which an IL4RA-binding ligand and a temperature-responsive disordered domain are repetitively linked, exhibits high selectivity in binding to IL4Ra, and the polypeptide-drug conjugate, in which a cytotoxic drug is bound to the polypeptide, demonstrates significantly enhanced cancer cell-killing efficacy and anti-tumor activity compared to unbound drugs or conventional anticancer agents, and has been confirmed to suppress drug resistance in cancer cells that are resistant to the anticancer agent temozolomide. Accordingly, the polypeptide-drug conjugate can be provided as an effective anticancer therapeutic agent for the treatment of tumors overexpressing IL4Ra and as a pharmaceutical composition for inhibiting drug resistance in cancer cells exhibiting resistance to anticancer drugs.

The utility model discloses engineering bacteria photo-thermal hydrogel smearing equipment which comprises a fixing frame, a smearing mechanism, a transmission mechanism and a uniform smearing part, the transmission mechanism is arranged on the fixing frame and can drive base layer cloth to transmit, the smearing mechanism can coat hydrogel and attach the hydrogel to the base layer cloth, and the uniform smearing part is located on one side of the smearing mechanism. The smearing mechanism can evenly smear hydrogel smeared on base layer cloth, the even smearing component comprises an even smearing plate and a lifting component, a gap exists between the even smearing plate and the conveying mechanism, and the lifting component can adjust the size of the gap between the even smearing plate and the conveying mechanism. The prepared hydrogel can be attached to the position needing to be treated, for example, the hydrogel can be applied to the fields of skin wounds and anti-cancer treatment.

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.

The present invention relates to a method for treating cancer, in which the anticancer effect is significantly enhanced by using a Toll-like receptor 7 or 8 agonist having the active site temporarily inactivated. The present invention provides a pharmaceutical composition for combination administration for preventing or treating cancer, comprising, as an active ingredient, a Toll-like receptor 7 or 8 agonist in which the active site is bound to cholesterol via a cleavable linker to be temporarily inactivated, wherein the pharmaceutical composition is administered after 1-20 days following anticancer treatment.

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of an inhibitor of nuclear import protein Karyopherin Beta 1 (Kpnβ1) such as the substituted pyrrolo[2,3-b]quinoxalines of Formula I and a therapeutically effective amount of an inhibitor of nuclear export protein Chromosome Maintenance 1 (Crm1) such as the hydrazide- containing compounds of Formula II. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of each of the nuclear transport inhibitors administered alone.

The invention relates to the technical field of application of glehnia littoralis, in particular to application of glehnia littoralis in preparation of drugs, and discloses new application of glehnia littoralis in preparation of drugs for preventing postoperative recurrence and metastasis of tumors, and the glehnia littoralis is applied to preparation of drugs for preventing postoperative recurrence and metastasis of tumors under the concentration of not causing cytotoxicity and toxic and side effects. Through multiple key steps of intervening tumor metastasis, including inhibition of adhesion of circulating tumor cells on vascular endothelial cells, inhibition of EMT transformation of the circulating tumor cells, inhibition of trans-endothelial migration of the circulating tumor cells and the like, the effect of preventing tumor metastasis or treating tumors is achieved, and meanwhile, the activity of immune cells is improved; the traditional Chinese medicine composition has the advantages of being capable of enhancing the killing ability of immune cells to circulating tumor cells, prolonging the lifetime, having extremely high safety, and solving the problems that the immune system and the rehabilitation ability are damaged in anti-cancer treatment by traditional medicines, the traditional cancer prevention and treatment strategy is limited and the like.

The application provides an active oxygen response type artificial ion channel, and a structural general formula is as follows: the application is activated by high level ROS in cancer cells, the activated channel promotes the synergistic transmembrane transmission of H + and Cl ‑ ions, thereby realizing specific anticancer treatment, the synthetic route of the application is green, simple, efficient, raw materials are easy to obtain, and can be used for synthesis of similar compounds.

Disclosed herein are methods for treating cancer with inhibitors of FN14 (e.g., Compound 1), or pharmaceutically acceptable salts thereof. The disclosure further provides methods of treating cancer with inhibitors of FN14 or pharmaceutically acceptable salts thereof, in combination with additional anti-cancer therapeutics (e.g., a kinase inhibitor).

The invention provides a chelating agent for use in a method of treating cancer in a subject, wherein said cancer has a resistance to an anti-cancer therapeutic agent. Further, the invention provides a chelating agent for use in a method of sensitizing a subject for an anti-cancer treatment and / or counteracting a resistance to an anti-cancer therapeutic agent, wherein the method restores or re-activates a tumor suppressor protein function that preferably was impaired due to aberrant tumor suppressor protein folding. The invention also provides a pharmaceutical composition comprising a 2,3-Dimercapto-1-propanesulfonic acid (DMPS) or DMSA, preferably miaDMSA, and a pharmaceutically acceptable excipient; wherein the DMPS is present in a dose of 40-12000 mg.

The invention belongs to the field of organic photoelectric materials, and particularly discloses a near-infrared two-region (NIR-II) multi-resonance hybrid four-free-radical molecule and preparation and application thereof, the structure of the molecule is as follows: in addition, the research on free radical materials in the aspect of NIR-II fluorescence imaging guided photo-thermal anticancer treatment is still limited, and the molecule has a wide application prospect. And the material is mainly concentrated on a double-free-radical material. A chain D-A-A-D type organic four-free-radical compound is designed and synthesized on the basis of a classical Cichibabin skeleton, the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound is high in stability and has the near-infrared two-region photoluminescence property, the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound is applied to research in biological photo-thermal anticancer treatment, and the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound has a wide application prospect. And the photo-thermal conversion efficiency of 87% is shown.

Mixing a low-viscosity solution and a high-viscosity solution was difficult. An object of the present invention is to provide a holder for mixed administration of at least two types of solutions for enhancing the radiation or anticancer therapeutic effect on a tumor, wherein the holder is capable of simultaneously discharging each solution at a constant ratio from respective syringes containing each solution.

A tumor-targeting protein or a fragment thereof, an antibody binding thereto and a use thereof are disclosed. A vector containing a nucleic acid coding for protein A56 or a fragment thereof, and a use thereof are disclosed. An antibody binding to protein A56 or a fragment thereof, and a use thereof are disclosed. The vector containing A56-encoding nucleic acid, a fragment thereof or a mutant thereof uses an oncolytic virus as the vector, and thus, when administered in an individual, specifically kills only cancer cells, primarily. In addition, cancer cells which have survived even after being infected with the oncolytic virus express the protein A56 on the cell surfaces thereof, and thus may be targeted for secondary anticancer therapy employing protein A56-encoding nucleic acid or protein A56 or a fragment thereof, or an antibody binding to A56.

Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.

The present invention relates to treatment of a cancer of the central nervous system, in particular the use of Wallerian degeneration inhibitors in the treatment of CNS cancer. Also provided are in vivo and in vitro methods of screening Wallerian degeneration inhibitors as anti-CNS cancer therapeutic compounds.

The present invention relates to a composition for the prevention or treatment of metastatic cancer, capable of inducing an abscopal effect, which is a systemic anticancer effect, in combination with radiotherapy to treat metastatic cancer that has spread from a primary cancer, wherein, by having confirmed that, upon radiotherapy in which a primary cancer site was irradiated with a low dose of radiation, the abscopal effect, which is a systemic anticancer effect, did not appear, whereas, when type 1 interferon was administered in combination with low-dose radiation to the primary cancer site, an anticancer effect appears even in non-radiated metastatic cancer sites, a composition comprising type 1 interferon is provided as a therapeutic agent or adjuvant for the treatment of metastatic cancer, which induces a systemic anticancer effect upon low-dose radiotherapy.

The present disclosure provides methods and compositions for treating cancer (e.g., lung cancer) in a subject by increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2) in the subject, or a functional fragment thereof. The present disclosure further provides methods of using PDLIM2 as a marker for determining and monitoring a subject's responsiveness to an anti-cancer treatment, providing a prognosis about a cancer in a subject, and selecting an effective anti-cancer treatment for a subject. The present disclosure also provides in vitro methods of screening anti-cancer agents by assessing whether the expression of PDLIM2 is restored by an anti-cancer agent in a cancer cell.

The present invention provides inhibitors of cell-expressed TDO2 and pharmaceutical compositions thereof, which can be used to modulate the activity of tryptophan 2,3-dioxygenase; treat immunosuppression; treat medical conditions that benefit from inhibition of tryptophan degradation; enhance the effectiveness of anti-cancer treatment including administration of anti-cancer agents; and treat tumor-specific immunosuppression associated with cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to a furo-quinoline dictamnine derivative as well as a preparation method and application thereof. The compound is novel and stable in structure, has a remarkable anti-cancer effect, particularly has a relatively high inhibition rate on NCI-H460 and 786-O tumor cells, has relatively low IC50, has a remarkable anti-tumor cell effect, and has a relatively good application prospect in the aspect of anti-cancer treatment. Besides, the preparation method of the furo-quinoline dictamnine derivative has the advantages of wide substrate application range, good functional group compatibility, mild reaction conditions, simplicity and convenience in operation and the like, can be used for large-scale industrial production, and has wide application value in the aspect of developing anti-cancer drugs.

The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

The description discloses selective and potent CDK 4 / 6 inhibitors that exhibit advantageous inhibition of cancer growth, even at low concentrations. One class of CDK 4 / 6 inhibitors refers to substituted pyrrolopyrimidine compounds having a fatty acid moiety and specifically derived from Palbociclib of the general formula [2A], where R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl; yn is an integer from 9 to 20. These compounds can be used as pharmaceutical compounds for anticancer therapies and are useful for the treatment, prevention and / or improvement of cancer.

The present invention relates to a composition comprising a TAF10 inhibitor for preventing or treating colorectal cancer. The inhibition of TAF10 was found to lead to suppressing the growth and proliferation of colorectal cancer cells, reducing vascularization, and inhibiting the WNT signaling pathway, and increase the survival rate of patients as analyzed with a large-scale cancer database. In particular, reversal of the cancerization process, which is the differentiation of colorectal cancer cells into normal cells, was confirmed. Unlike conventional anticancer agents that simply induce the death of cancer cells, the present invention can thus be advantageously utilized as a treatment method for converting colorectal cancer cells into normal cells while excluding side effects of normal cell death that may occur during anticancer treatment.

The present invention relates to a method of assessing or monitoring the response of a patient suffering from cancer after receiving an anti-cancer treatment, said method being based on the detection of biomarkers. The invention also relates to a kit for carrying out said method and to a method for treating said patient.